Clearside Biomedical

Clearside Biomedical OCF/Debt

Delisted

The Operating Cash Flow to Debt Ratio of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -1,325.25 %. In the previous year, Operating Cash Flow to Debt Ratio was -525.63 % — a change of 152.13% (lower).

OCF/Debt

-1,325.25 %

YoY

152.13%

Last updated:

Operating Cash Flow to Debt Ratio of Clearside Biomedical is 2020 -1,325.25 % . Operating Cash Flow to Debt Ratio of Clearside Biomedical was 2019 -525.63 % . It decreases by 152.13% lower compared to the previous year.

The Clearside Biomedical OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2015
-232.44 USD
Jan 1, 2016
-299.21 USD
Jan 1, 2017
-637.70 USD
Jan 1, 2018
-793.59 USD
Jan 1, 2019
-525.63 USD
Jan 1, 2020
-1,325.25 USD
The Clearside Biomedical OCF/Debt history
YEAROCF/DebtYoY
-1,325.25 %+152.13%
-525.63 %-33.77%
-793.59 %+24.44%
-637.70 %+113.13%
-299.21 %+28.72%
-232.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Operating Cash Flow to Debt Ratio of Clearside Biomedical is -1,325.25 % in 2020.

Operating Cash Flow to Debt Ratio of Clearside Biomedical changed from -525.63 % to -1,325.25 %, representing a 152.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Clearside Biomedical

All Key Metrics — Clearside Biomedical